Diagen signs new distribution agreement with SpeeDx
Oct 24 2017 Comments 0
Sydney, Australia-based SpeeDx has announced a distribution agreement with Scandinavian clinical laboratory supplier Diagen to supply its polymerae chain reaction product lines to hospitals and research facilities across Sweden, Norway and Denmark.
The PlexPCR® range will allow Diagen’s customers to obtain complex diagnostic information on sexually transmitted infections or other infectious diseases from a single, cost-effective test. The agreement will also give them access to the ResistancePlus MG assay. This is the first CE-IVD test to simultaneously detect Mycoplasma genitalium and genetic markers for azithromycin resistance, as recommended by the new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.
“Scandinavia is home to some important thought leaders influencing sexual health and STI testing practices across Europe,” said Colin Denver, CEO of SpeeDx. “We see our partnership with Diagen as key to offering the best service to laboratories across these important markets.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In this Issue Articles - How to Achieve Ultimate PCR Optimisation Spotlight Features - Incubators, Freezers & Cooling Equipment - Balances & Strain Gauges - Proteomics, Genomics & Mic...
View all digital editions
Jan 21 2018 Palm Springs, CA, USA
Jan 24 2018 Cardiff, UK
Jan 29 2018 Dubai International Convention & Exhibition Centre
Feb 03 2018 San Diego, CA USA
Feb 05 2018 Dubai, UAE